Longeveron Inc. (NASDAQ:LGVN) Director Sells $60,450.00 in Stock

Longeveron Inc. (NASDAQ:LGVN – Get Rating) Director Rock Soffer sold 7,500 shares of the business’s stock in a transaction that occurred on Friday, May 20th. The shares were sold at an average price of $8.06, for a total value of $60,450.00. Following the completion of the sale, the director now directly owns 684,351 shares in the company, valued at approximately $5,515,869.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Rock Soffer also recently made the following trade(s):

• On Monday, May 23rd, Rock Soffer sold 8,000 shares of Longeveron stock. The shares were sold at an average price of $7.78, for a total value of $62,240.00.

Shares of NASDAQ:LGVN traded down $0.36 during trading on Tuesday, hitting $7.52. The company’s stock had a trading volume of 122,901 shares, compared to its average volume of 3,652,006. The business has a 50 day moving average price of $9.15 and a two-hundred day moving average price of $10.50. The company has a market capitalization of $157.26 million, a PE ratio of -8.55 and a beta of -2.05. Longeveron Inc. has a fifty-two week low of $2.84 and a fifty-two week high of $45.00.

Longeveron (NASDAQ:LGVN – Get Rating) last posted its quarterly earnings results on Friday, May 13th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.04. Longeveron had a negative net margin of 1,341.85% and a negative return on equity of 58.76%. During the same period in the prior year, the business earned ($0.18) earnings per share. On average, equities analysts predict that Longeveron Inc. will post -0.7 earnings per share for the current year.

Separately, Maxim Group initiated coverage on Longeveron in a research report on Thursday, March 24th. They issued a “buy” rating and a $14.00 target price on the stock.

Several large investors have recently bought and sold shares of the business. Royal Bank of Canada acquired a new position in shares of Longeveron in the second quarter worth $28,000. Geode Capital Management LLC grew its stake in shares of Longeveron by 26.7% during the fourth quarter. Geode Capital Management LLC now owns 27,289 shares of the company’s stock worth $329,000 after purchasing an additional 5,759 shares in the last quarter. UBS Group AG grew its stake in shares of Longeveron by 272.9% during the third quarter. UBS Group AG now owns 9,633 shares of the company’s stock worth $34,000 after purchasing an additional 7,050 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of Longeveron during the fourth quarter worth $122,000. Finally, Virtu Financial LLC acquired a new position in shares of Longeveron during the fourth quarter worth $137,000. Institutional investors and hedge funds own 2.20% of the company’s stock.

About Longeveron (Get Rating)

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors.

Featured Stories